UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2016

Aduro Biotech, Inc.
(Exact name of registrant as specified in its charter)

Delaware	**001-37345**	**94-3348934**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

626 Bancroft Way, 3C **Berkeley, California**	**94710**
(Address of principal executive offices)	**(Zip Code)**

Registrant's telephone number, including area code: (510) 848-4400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

Aduro Biotech, Inc. (the "**Company**") is furnishing the Investor Presentation, dated January 11, 2016, attached as Exhibit 99.1 to this Current Report on Form 8-K, which the Company may use from time to time in presentations to investors and other stakeholders.

The information in Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless Aduro expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit	Description
99.1	Investor Presentation of Aduro Biotech, Inc., dated January 11, 2016.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 11, 2016

ADURO BIOTECH, INC.

By: /s/ Jennifer Lew
Jennifer Lew
Senior Vice President of Finance

EXHIBIT INDEX

Exhibit	Description
99.1	Investor Presentation of Aduro Biotech, Inc., dated January 11, 2016.

Exhibit 99.1

ADURO BIOTECH™

Engineered Immunotherapy for Cancer

Company Overview

January 2016

www.aduro.com

Disclaimer

Special Note Regarding Forward-Looking Statements

This presentation and the accompanying oral presentation include express and implied forward-looking statements regarding the current expectations, estimates, opinions and beliefs of Aduro Biotech, Inc. ("Aduro") that are not historical facts. These forward-looking statements include statements regarding Aduro's expectations for its product candidates (including their therapeutic and commercial potential, anticipated future development activities, anticipated timing of development activities, the indications Aduro and its collaborators plan to pursue, anticipated submissions to the U.S. Food and Drug Administration, potential for eventual regulatory approval, commercialization and launch of Aduro's product candidates), future results of operations and financial position, business strategy, strategic collaborations, any royalty or milestone payments and Aduro's ability to obtain and maintain intellectual property protection for its product candidates. Such forward-looking statements may be identified by words such as "believes", "may", "will", "expects", "endeavors", "anticipates", "intends", "plans", "estimates", "projects", "should", "objective" and variations of such words and similar words. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, Aduro's history of net operating losses and uncertainty regarding its ability to achieve profitability, Aduro's ability to develop and commercialize its product candidates, Aduro's ability to use and expand its technology platforms to build a pipeline of product candidates, Aduro's dependence on its lead product candidate, CRS-207, and GVAX Pancreas, Aduro's ability to obtain and maintain regulatory approval of its product candidates, Aduro's inability to operate in a competitive industry and compete successfully against competitors that have greater resources than it does, Aduro's reliance on third parties, and Aduro's ability to obtain and adequately protect intellectual property rights for its product candidates. Aduro discusses many of these risks in greater detail under the heading "Risk Factors" contained in its most recent Quarterly Report on Form 10-Q which is on file with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Aduro's actual results of operations, financial condition and liquidity, and the development of the industry in which Aduro operates, may differ materially from the forward-looking statements contained in this presentation and the accompanying oral presentation. Any forward-looking statements that Aduro makes in this presentation and the accompanying oral presentation speak only as of the date of these presentations. Except as required by law, Aduro assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date hereof.

Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Aduro or any director, employee, agent, or adviser of Aduro. This presentation does not purport to be all-inclusive or to contain all of the information you may desire.

Aduro Highlights

- Three diverse and versatile immunotherapy platforms
  - **LADD** – **novel, live-attenuated *Listeria* platform to deliver tumor antigens**
    - Survival benefit demonstrated in randomized Phase 2 trial in pancreatic cancer trial
    - 94% disease control rate in Phase 1b mesothelioma trial
    - Two Phase 1 trials in lung and prostate cancer underway by Janssen Pharmaceuticals
    - Phase 1/2 trial in ovarian cancer planned in collaboration with Incyte
  - **CDN** – **small molecule immune modulators with broad therapeutic potential**
    - Major oncology collaboration with Novartis
    - Phase 1 trial in accessible tumors planned
    - Maintain rights in all ex-oncology areas, including autoimmune and infectious diseases
  - **B-select mAbs** – **acquired proprietary technology and preclinical assets**
    - Multiple checkpoint inhibitors and receptor-activating agonists
- Strategies for monotherapies and combination regimens
- Strong financial and IP position

2015 Accomplishments

- Corporate achievements
  - ✓ Raised ~$175 million in Series D and IPO
  - ✓ Signed $750M CDN collaboration with Novartis targeting STING pathway in oncology
  - ✓ Acquired BioNovion, a monoclonal antibody company; launched Aduro Biotech Europe
- Clinical achievements
  - ✓ Published Phase 2a pancreatic cancer results in the Journal of Clinical Oncology
  - ✓ Initiated Phase 2b STELLAR trial in pancreatic cancer
  - ✓ Completed enrollment in Phase 2b ECLIPSE trial in pancreatic cancer
  - ✓ Received Orphan Drug Designation in the EU for CRS-207 in pancreatic cancer
  - ✓ Received Orphan Drug Designation in the US and EU for CRS-207 in mesothelioma
  - ✓ Completed enrollment in Phase 1b trial in mesothelioma
  - ✓ Reported Phase 1b mesothelioma results at ASCO and ESMO/ECC 2015
  - ✓ Signed clinical trial agreement with Incyte to develop combination therapy in ovarian cancer
  - ✓ Phase 1 trials in prostate (ADU-741) and lung cancer (ADU-214) in collaboration with Janssen

Aduro's Place in Cancer Therapy

Immuno-oncology is Transforming the Treatment of Cancer

- Physicians and scientists are changing the way they think about the biology and treatment of cancer
- Emerging paradigm: Combinations of conventional and novel immuno-oncology therapies aimed to improve cancer patient survival



- Aduro has the potential to assume an important role in the transformation of cancer care with its proprietary immuno-oncology platform technologies

1) Source: Zinkernagel et al, Frontiers in fimmu 2014.
2) Source: Ribas et al, Clin Cancer Res 2012, 18:336.

ADURO BIOTECH

Enhancing Therapeutic Strength through Combinations

Breadth of Potential Combinations with Conventional and Novel Therapies



ADURO BIOTECH

LADD Platform: Promising Vector to Induce Innate & Adaptive Immunity

Live, Attenuated, Double-Deleted Listeria Monocytogenes

- Proprietary gene engineering for safety and efficacy
  - Deletion of two virulence genes substantially reduces disease-causing properties
  - Multivalent antigen cassettes for antigen expression
  - Favorable safety profile in trials to date
- Induces robust immune response
  - Broad innate response (cytokines, chemokines and NK cells)
  - Antigen-specific adaptive T-cell response (CD4+ and CD8+ T cells)
- Promising clinical results
  - Survival benefit in randomized Phase 2a trial in pancreatic cancer with GVAX Pancreas
  - 94% disease control rate in Phase 1b trial in mesothelioma
- Extensive platform potential
  - Current clinical trials in mesothelioma, pancreatic, lung, prostate and ovarian cancer
  - Ability to engineer strains with multiple tumor-specific antigens for future indications
  - Cost-effective manufacturing process
- Versatile combination strategy using conventional and novel therapies
  - Near-term clinical evaluation with checkpoint, IDO inhibitors and chemotherapy

LADD Platform

Stimulates Innate Immunity Responses and Antigen-specific T Cell Responses



ADURO BIOTECH

CDN Platform: Off-the-Shelf Patient Specific Immunity

Cyclic Dinucleotide Small Molecule Immune Modulators

- Targets and activates STING – central mediator of innate immunity
- Proprietary synthetic CDN structures
  - Activate all known human STING receptors
  - Synthetic compounds more potent than natural STING ligands
- Significant anti-tumor activity in pre-clinical models
  - Induce durable antigen-specific T cell immunity
  - Promising activity against both treated and distal tumors
- Multiple product opportunities
  - Potential as single agent and combination therapy
  - Small molecule approach to patient-specific immunotherapy
  - Developing formulations to enable systemic delivery

CDNs Activate Innate & Adaptive Immunity through STING



ADURO BIOTECH

B-select Monoclonal Antibodies

Targets First- or Best-in-Class Agonist and Antagonist mAbs





ADURO BIOTECH

Aduro's Development Pipeline

Program	Indication	Combination	Discovery / Preclinical	Phase 1	Phase 2	Phase 3
LADD Programs						
CRS-207	Pancreatic	GVAX				
	Pancreatic	GVAX+αPD-1				
	Mesothelioma	Chemo				
	Ovarian	Epacadostat				Incyte
ADU-623	Glioblastoma	None				
ADU-741	Prostate	TBD				janssen
ADU-214	Lung	Multiple / TBD				janssen
CDN Programs						
ADU-S100	Palpable tumors					NOVARTIS
Adjuvant	Infectious Disease					
STING-Blok	Autoimmune					
B-select Programs						
Anti-APRIL	Oncology					
Anti-CTLA4	Oncology					
Anti-CD27 agonist	Oncology					**Partnered**
Anti-PD1	Oncology					
Anti-CD70	Oncology					**Partnered**
Bispecific Ab	Oncology					Genmab

ADURO BIOTECH

Clinical Programs

CRS-207: LADD Strain Expressing Mesothelin Tumor Antigen

ADURO BIOTECH

CRS-207: Pancreatic Cancer

FDA Breakthrough Therapy; US and EU Orphan Drug Designations

- Phase 2a: CRS-207 + GVAX (Completed)
  - Demonstrated survival benefit vs. GVAX Pancreas alone
  - Favorable safety profile to date
  - Continue to treat and monitor long-term survivors

ECLIPSE

- Phase 2b: CRS-207 + GVAX (Fully Enrolled)
  - Primary endpoint: Overall survival superiority vs. chemotherapy control
  - Quality of life evaluation
  - Top line results expected late Q2 2016

STELLAR

- Phase 2b: αPD-1 + CRS-207 + GVAX (Ongoing)
  - Primary endpoint: Overall survival benefit with anti-PD-1 (nivolumab)
  - Interim analysis expected 2H 2016
  - Investigator-sponsored study supported by Aduro, Bristol-Myers Squibb, Stand Up to Cancer, PanCAN/AACR and Lustgarten Foundation

ADURO BIOTECH

CRS-207: Pancreatic Cancer

Promising Phase 2a Results with Long-Term Survivors



Subjects may continue on additional courses of treatment if clinically stable



Data as of October 2013

Long-term follow-up data:

- Seven patients treated with the GVAX/CRS-207 regimen survived for over three years
- One patient continues to receive GVAX/CRS-207 treatment combination

ADURO BIOTECH

CRS-207: Pancreatic Cancer

Comprehensive Phase 2b Trial Fully Enrolled



- Primary endpoint: Overall survival in Arm A vs Arm C (third line)
- Statistical design: 80% power, hazard ratio=0.67, α=0.15 (one-sided)
- Secondary endpoints include: Safety, progression-free survival, tumor response rate and quality of life
- Top line data expected late Q2 2016

ADURO BIOTECH

CRS-207: Pancreatic Cancer

Preclinical and Early Clinical Studies Support Combination with Checkpoint Inhibitors



Patients may continue on additional courses of treatment if clinically stable

- Primary endpoint: Overall survival
- Secondary endpoints: Clinical response and safety
- Interim data expected to be reported in 2H 2016
- Investigator-sponsored study supported by Aduro, Bristol-Myers Squibb, Stand Up to Cancer, PanCAN/AACR and Lustgarten Foundation

ADURO BIOTECH

CRS-207: Pancreatic Cancer

Phase 3 Planning and Manufacturing

- Trial design concept
  - Global study in metastatic pancreatic cancer patients who received prior chemotherapy
    - Opportunity to evaluate as a second-line therapy
  - Primary endpoint: Overall survival
  - Final design based on ECLIPSE results
  - Finalize plan in 2H 2016



- Technology transfer to CMOs
  - IDT Biologika (CRS-207)
  - Lonza (GVAX Pancreas)

CRS-207: Mesothelioma

Strong Disease Control Signal in Phase 1b; US and EU Orphan Drug Designations

- Phase 1b: Front line combination of CRS-207 and chemotherapy (Fully Enrolled)
  - Single arm trial in combination with SOC chemotherapy
  - Safety and efficacy data updated at ESMO 2015
  - 59% partial response rate, 94% disease control rate in front line patients
  - Sites remain open for continued exploratory evaluation of CRS-207 with low-dose cyclophosphamide
- Phase 3: Front line CRS-207 and chemotherapy combination (Planned)
  - Global randomized trial
    - Primary objective: Efficacy of CRS-207+pem/cis vs pem/cis
      - Objective modified RECIST response rate
      - Overall survival
    - Secondary objectives: Include PFS, improvements in pulmonary function and symptom burden and QOL
  - North America, Europe and Australia

CRS-207: Mesothelioma

Phase 1b Clinical Trial in Mesothelioma

38 enrolled with non-resectable malignant pleural mesothelioma patients with no prior treatment (5 sites, U.S.)



Patients may continue CRS-207 maintenance vaccines every 8 weeks if clinically stable

- Primary endpoints: Safety and immune response
- Secondary endpoints: Tumor response, time to progression, progression-free survival, overall survival, immune analyses, tumor marker kinetics
- Survival results expected in 1H 2016

ADURO BIOTECH

CRS-207: Mesothelioma

Best Overall Response of Target Lesions



ESMO 2015

ADURO BIOTECH

CRS-207 + Epacadostat: Ovarian Cancer

Planned Phase 1/2 Trial Design



Patients may continue on additional courses of treatment if clinically stable

ADURO BIOTECH

Cyclic Dinucleotides (CDN)

Small Molecules Targeting STING (Stimulator of Interferon Genes)

ADURO BIOTECH

First-in-Human Clinical Study to Target STING

ADU-S100 Clinical Trial in H1 2016

- ADU-S100 induces innate immunity through STING
- STING is the critical receptor to activate immune cells including dendritic cells in the tumor microenvironment
- IT injection of ADU-S100 leads to an “inflamed” tumor phenotype characterized by infiltrating T lymphocytes
- IT injection of ADU-S100 stimulates priming of CD8+ T cells specific for any individuals’ unique neo-antigens
- ADU-S100 is an off-the-shelf small molecule approach to patient-specific immunotherapy



Corrales and Gajewski., *2015, Clin. Can. Res.*

ADURO BIOTECH

CDN: Encouraging Preclinical Data

Activity in B16 Melanoma Tumor Model Significantly Better than TLR Ligands



ADURO BIOTECH

CDN: Protective Immunity in Preclinical Model

Immunity in Lung Metastases Following IT Injection of Primary Tumor





- B16 subcutaneous injection in the flank (Day 0) followed by IV injection (Day 7)
- ADU-S100 IT treatment course (Days 14, 17, 21) on primary flank tumor

ADURO BIOTECH

ADU-S100: Solid Tumors or Lymphomas

Phase 1 STING Agonist Clinical Trial



- Two-part study to assess the safety/tolerability in patients with cutaneously accessible, treatment-refractory primary or metastatic solid tumors or lymphomas
  - Part 1: dose escalation in cohorts of 3-6 pts
  - Part 2: dose expansion arms to better characterize safety/efficacy
- Potential future combinations include immune checkpoint inhibitors and chemo/radiotherapy

ADURO BIOTECH

Cyclic Dinucleotides (CDN)

Breadth of Potential Product and Combination Opportunities



ADURO BIOTECH

Acquisition, Collaborations and Intellectual Property

ADURO BIOTECH

Acquisition of BioNovion in 2015

Monoclonal Antibody Discovery and Development

ADURO BIOTECH Europe

- Immunotherapy pipeline includes assets that inhibit clinically validated immune checkpoint pathways
- May be used alone or in combination with the LADD and CDN platforms to increase immunotherapy potency and durability
- Broad library of therapeutic antibodies
  - APRIL inhibitor, a survival factor relevant to hematologic malignancies
  - Immune checkpoint inhibitors targeting PD1, CTLA4 and other pathways
  - Additional inhibitors and agonists targeting pathways that modulate both innate and adaptive regulators of the immune response
- Existing collaboration with Genmab
- Proven track record of successful antibody development
- Launched Aduro Biotech Europe

Robust Collaboration with Janssen Pharmaceuticals

Two Major LADD Collaborations Executed in 2014

- Initiated two Phase 1 trials in lung and prostate cancer using LADD candidates (ADU-214 and ADU-741)
- Prostate Cancer
  - Global License to ADU-741 and permitted derivatives
  - $12M upfront
  - $365M total upfront and potential milestones
  - Tiered mid single-digit to low teens royalties
- Lung Cancer
  - Global License to ADU-214 and permitted derivatives
  - $30M upfront
  - $817M total upfront and potential milestones
  - Tiered high single-digit to low teens royalties
- Validates versatility of LADD platform technology

Major STING Oncology Collaboration with Novartis

Co-Development, Co-Commercialization, Aduro Books U.S. Sales

- Structure
  - Worldwide covering STING agonists from either company for oncology
  - Joint research and development
  - Aduro leads U.S. commercialization and books U.S. sales
  - NVS leads ex-U.S. commercialization and books ex-U.S. sales
- Financial Terms
  - $200M upfront
  - $50M equity investment
  - Up to $500M in development milestones
  - Profit/expense share U.S., major European countries and Japan; royalties ROW
- Aduro retains all rights to CDN technology platform outside of oncology

Aduro Maintains Global Rights to Broad Portfolio

- Including Lead LADD Programs in Pancreatic Cancer and Mesothelioma
- CRS-207 (mesothelin antigen)
  - Pancreatic cancer: Breakthrough Therapy designation with GVAX Pancreas
  - Mesothelioma: Strong Phase 1b response data
  - Additional mesothelin-expressing cancers: i.e. ovarian cancer
- ADU-623 (NYESO-1 and EGFRvIII antigens)
  - Glioblastoma: Ongoing Phase 1 clinical trial
- LADD platform expansion to target additional cancer types
  - New product candidates with proprietary antigen combinations under evaluation
- CDNs in significant therapeutic areas beyond oncology
  - Autoimmune diseases
  - Infectious diseases
- B-select mAbs may be used alone or in combination with LADD and CDN platforms in multiple cancer types

Intellectual Property and Exclusivity in the United States

Extensive Patent Portfolio and Favorable Regulatory Designations

- Global Rights (inclusive of in-licensed patents)
  - >200 issued composition and methods patents
  - >50 pending applications

Technology	Nominal Expiration	Market and Data Exclusivity	Additional Protection
LADD	2022-27	• Orphan Drug *(CRS-207 for the treatment of Pancreatic Cancer and Mesothelioma)* • Biosimilars Act	• Proprietary Strains • Manufacturing
CDN	2025-36	• TBD	• Manufacturing • Formulation
GVAX	2016-22	• Orphan Drug *(GVAX Pancreas for the treatment of Pancreatic Cancer)* • Biosimilars Act	• Proprietary Cell Lines • Manufacturing

As of March 31, 2015

Financials and Milestones

ADURO BIOTECH

2015 Financials

Strong Financial Position

Cash & cash equivalents as of 9/30/2015	$448.4 M
Operating expenses through 9/30/2015	$55.0 M
Shares outstanding as of 9/30/2015	62.3 M

Upcoming Milestones

Significant Catalysts Expected in 2016

		Q1 2016	Q2 2016	H1 2016	H2 2016
CRS-207 for Pancreatic Cancer	ECLIPSE (GVAX Pancreas + CRS-207)				
	Report Phase 2b top line results		★		
	STELLAR (nivolumab + GVAX Pancreas + CRS-207)				
	Report Phase 2b interim analysis				★
	Finalize Phase 3 trial design				★
CRS-207 for Mesothelioma	Report final Phase 1b top line results			★	
	Initiate randomized global Phase 3 clinical trial		★		
ADU-S100 for Multiple Cancers	Initiate Phase 1 trial in collaboration with Novartis			★	
CRS-207 + Epacadostat for Ovarian Cancer	Initiate Phase 1 trial in collaboration with Incyte	★			
Janssen Milestone Payments	Clinical progress			★	
Novartis Milestone Payment	Phase 1 trial initiation			★	

ADURO BIOTECH

Aduro Highlights

- Three diverse and versatile immunotherapy platforms
  - **LADD** – **novel, live-attenuated *Listeria* platform to deliver tumor antigens**
    - Survival benefit demonstrated in randomized Phase 2 trial in pancreatic cancer trial
    - 94% disease control rate in Phase 1b mesothelioma trial
    - Two Phase 1 trials in lung and prostate cancer underway by Janssen Pharmaceuticals
    - Phase 1/2 trial in ovarian cancer planned in collaboration with Incyte
  - **CDN** – **small molecule immune modulators with broad therapeutic potential**
    - Major oncology collaboration with Novartis
    - Phase 1 trial in accessible tumors planned
    - Maintain rights in all ex-oncology areas, including autoimmune and infectious diseases
  - **B-select mAbs** – **acquired proprietary technology and preclinical assets**
    - Multiple checkpoint inhibitors and receptor-activating agonists
- Strategies for monotherapies and combination regimens
- Strong financial and IP position

ADURO BIOTECH™

Engineered Immunotherapy for Cancer

Company Overview

January 2016

www.aduro.com